BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

201 related articles for article (PubMed ID: 17264127)

  • 1. Characterization of in vitro and in vivo hypomethylating effects of decitabine in acute myeloid leukemia by a rapid, specific and sensitive LC-MS/MS method.
    Liu Z; Liu S; Xie Z; Blum W; Perrotti D; Paschka P; Klisovic R; Byrd J; Chan KK; Marcucci G
    Nucleic Acids Res; 2007; 35(5):e31. PubMed ID: 17264127
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Development, validation, and clinical application of a high-performance liquid chromatography-tandem mass spectrometry assay for the quantification of total intracellular β-decitabine nucleotides and genomic DNA incorporated β-decitabine and 5-methyl-2'-deoxycytidine.
    Roosendaal J; Rosing H; Lucas L; Oganesian A; Schellens JHM; Beijnen JH
    J Pharm Biomed Anal; 2019 Feb; 164():16-26. PubMed ID: 30366147
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Quantification of regional DNA methylation by liquid chromatography/tandem mass spectrometry.
    Liu Z; Wu J; Xie Z; Liu S; Fan-Havard P; Huang TH; Plass C; Marcucci G; Chan KK
    Anal Biochem; 2009 Aug; 391(2):106-13. PubMed ID: 19442645
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Fused-core silica column ultra-performance liquid chromatography-ion trap tandem mass spectrometry for determination of global DNA methylation status.
    Yang I; Fortin MC; Richardson JR; Buckley B
    Anal Biochem; 2011 Feb; 409(1):138-43. PubMed ID: 20950581
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A pharmacodynamic assay to monitor treatment with the hypomethylating cytosine analogs, decitabine and azacitidine.
    Jacobberger JW; Woost PG
    Methods Cell Biol; 2024; 186():131-150. PubMed ID: 38705597
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Decitabine effect on tumor global DNA methylation and other parameters in a phase I trial in refractory solid tumors and lymphomas.
    Stewart DJ; Issa JP; Kurzrock R; Nunez MI; Jelinek J; Hong D; Oki Y; Guo Z; Gupta S; Wistuba II
    Clin Cancer Res; 2009 Jun; 15(11):3881-8. PubMed ID: 19470736
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In vivo effects of decitabine in myelodysplasia and acute myeloid leukemia: review of cytogenetic and molecular studies.
    Hackanson B; Robbel C; Wijermans P; Lübbert M
    Ann Hematol; 2005 Dec; 84 Suppl 1():32-8. PubMed ID: 16292549
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of MLL5 expression on decitabine efficacy and DNA methylation in acute myeloid leukemia.
    Yun H; Damm F; Yap D; Schwarzer A; Chaturvedi A; Jyotsana N; Lübbert M; Bullinger L; Döhner K; Geffers R; Aparicio S; Humphries RK; Ganser A; Heuser M
    Haematologica; 2014 Sep; 99(9):1456-64. PubMed ID: 24895338
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Simultaneous quantitative determination of 5-aza-2'-deoxycytidine genomic incorporation and DNA demethylation by liquid chromatography tandem mass spectrometry as exposure-response measures of nucleoside analog DNA methyltransferase inhibitors.
    Anders NM; Liu J; Wanjiku T; Giovinazzo H; Zhou J; Vaghasia A; Nelson WG; Yegnasubramanian S; Rudek MA
    J Chromatogr B Analyt Technol Biomed Life Sci; 2016 Jun; 1022():38-45. PubMed ID: 27082761
    [TBL] [Abstract][Full Text] [Related]  

  • 10. p53-inducible ribonucleotide reductase (p53R2/RRM2B) is a DNA hypomethylation-independent decitabine gene target that correlates with clinical response in myelodysplastic syndrome/acute myelogenous leukemia.
    Link PA; Baer MR; James SR; Jones DA; Karpf AR
    Cancer Res; 2008 Nov; 68(22):9358-66. PubMed ID: 19010910
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Genome-wide methylation profiling in decitabine-treated patients with acute myeloid leukemia.
    Yan P; Frankhouser D; Murphy M; Tam HH; Rodriguez B; Curfman J; Trimarchi M; Geyer S; Wu YZ; Whitman SP; Metzeler K; Walker A; Klisovic R; Jacob S; Grever MR; Byrd JC; Bloomfield CD; Garzon R; Blum W; Caligiuri MA; Bundschuh R; Marcucci G
    Blood; 2012 Sep; 120(12):2466-74. PubMed ID: 22786882
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tracking Decitabine Incorporation into Malignant Myeloid Cell DNA in vitro and in vivo by LC-MS/MS with Enzymatic Digestion.
    Chilakala S; Feng Y; Li L; Mahfouz R; Quteba E; Saunthararajah Y; Xu Y
    Sci Rep; 2019 Mar; 9(1):4558. PubMed ID: 30872721
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Decitabine induces very early in vivo DNA methylation changes in blasts from patients with acute myeloid leukemia.
    Claus R; Pfeifer D; Almstedt M; Zucknick M; Hackanson B; Plass C; Lübbert M
    Leuk Res; 2013 Feb; 37(2):190-6. PubMed ID: 23158571
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical results with the DNA hypomethylating agent 5-aza-2'-deoxycytidine (decitabine) in patients with myelodysplastic syndromes: an update.
    Joeckel TE; Lübbert M
    Semin Hematol; 2012 Oct; 49(4):330-41. PubMed ID: 23079063
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A comparison of azacitidine and decitabine activities in acute myeloid leukemia cell lines.
    Hollenbach PW; Nguyen AN; Brady H; Williams M; Ning Y; Richard N; Krushel L; Aukerman SL; Heise C; MacBeth KJ
    PLoS One; 2010 Feb; 5(2):e9001. PubMed ID: 20126405
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hypomethylating agents reactivate FOXO3A in acute myeloid leukemia.
    Thépot S; Lainey E; Cluzeau T; Sébert M; Leroy C; Adès L; Tailler M; Galluzzi L; Baran-Marszak F; Roudot H; Eclache V; Gardin C; de Botton S; Auberger P; Fenaux P; Kroemer G; Boehrer S
    Cell Cycle; 2011 Jul; 10(14):2323-30. PubMed ID: 21654193
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Gemcitabine reactivates epigenetically silenced genes and functions as a DNA methyltransferase inhibitor.
    Gray SG; Baird AM; O'Kelly F; Nikolaidis G; Almgren M; Meunier A; Dockry E; Hollywood D; Ekström TJ; Perry AS; O'Byrne KJ
    Int J Mol Med; 2012 Dec; 30(6):1505-11. PubMed ID: 23007409
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Analysis of genome-wide methylation and gene expression induced by 5-aza-2'-deoxycytidine identifies BCL2L10 as a frequent methylation target in acute myeloid leukemia.
    Fabiani E; Leone G; Giachelia M; D'alo' F; Greco M; Criscuolo M; Guidi F; Rutella S; Hohaus S; Voso MT
    Leuk Lymphoma; 2010 Dec; 51(12):2275-84. PubMed ID: 21077739
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The role of hypomethylating agents in the treatment of elderly patients with AML.
    Al-Ali HK; Jaekel N; Niederwieser D
    J Geriatr Oncol; 2014 Jan; 5(1):89-105. PubMed ID: 24484723
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeting epigenetic pathways in acute myeloid leukemia and myelodysplastic syndrome: a systematic review of hypomethylating agents trials.
    Yun S; Vincelette ND; Abraham I; Robertson KD; Fernandez-Zapico ME; Patnaik MM
    Clin Epigenetics; 2016; 8():68. PubMed ID: 27307795
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.